JP2003512426A - 双極性気分障害における躁病の治療のための１−アミノインダンの使用。 - Google Patents
双極性気分障害における躁病の治療のための１−アミノインダンの使用。Info
- Publication number
- JP2003512426A JP2003512426A JP2001532759A JP2001532759A JP2003512426A JP 2003512426 A JP2003512426 A JP 2003512426A JP 2001532759 A JP2001532759 A JP 2001532759A JP 2001532759 A JP2001532759 A JP 2001532759A JP 2003512426 A JP2003512426 A JP 2003512426A
- Authority
- JP
- Japan
- Prior art keywords
- administration
- salt
- alkyl
- hydrogen
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010026749 Mania Diseases 0.000 title claims abstract description 19
- XJEVHMGJSYVQBQ-UHFFFAOYSA-N 2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(N)CCC2=C1 XJEVHMGJSYVQBQ-UHFFFAOYSA-N 0.000 title claims abstract description 10
- 208000020925 Bipolar disease Diseases 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 7
- DBGKPDNKZZGWOM-JTQLQIEISA-N n-[(1s)-2,3-dihydro-1h-inden-1-yl]formamide Chemical compound C1=CC=C2[C@@H](NC=O)CCC2=C1 DBGKPDNKZZGWOM-JTQLQIEISA-N 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- BKAZIFPIBFUJFU-UHFFFAOYSA-N 2-amino-n-(2,3-dihydro-1h-inden-1-yl)acetamide Chemical compound C1=CC=C2C(NC(=O)CN)CCC2=C1 BKAZIFPIBFUJFU-UHFFFAOYSA-N 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 238000007912 intraperitoneal administration Methods 0.000 claims description 11
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 claims description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- UOOXDDHYFFXMJJ-UHFFFAOYSA-N n-(2,3-dihydro-1h-inden-1-yl)acetamide Chemical compound C1=CC=C2C(NC(=O)C)CCC2=C1 UOOXDDHYFFXMJJ-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 description 49
- 241000700159 Rattus Species 0.000 description 29
- UOOXDDHYFFXMJJ-LLVKDONJSA-N n-[(1r)-2,3-dihydro-1h-inden-1-yl]acetamide Chemical compound C1=CC=C2[C@H](NC(=O)C)CCC2=C1 UOOXDDHYFFXMJJ-LLVKDONJSA-N 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 16
- 230000033001 locomotion Effects 0.000 description 14
- BKAZIFPIBFUJFU-JTQLQIEISA-N 2-amino-N-[(1S)-2,3-dihydro-1H-inden-1-yl]acetamide Chemical compound C1CC2=CC=CC=C2[C@H]1NC(=O)CN BKAZIFPIBFUJFU-JTQLQIEISA-N 0.000 description 13
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 11
- 229940025084 amphetamine Drugs 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000000540 analysis of variance Methods 0.000 description 8
- 238000001647 drug administration Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000000857 drug effect Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 230000001550 time effect Effects 0.000 description 7
- 230000006742 locomotor activity Effects 0.000 description 6
- 206010011953 Decreased activity Diseases 0.000 description 3
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- -1 2-aminoacetyl Chemical group 0.000 description 2
- MAYMVHAVYDCEHG-UHFFFAOYSA-N 3-amino-2,3-dihydro-1h-inden-4-ol Chemical class C1=CC(O)=C2C(N)CCC2=C1 MAYMVHAVYDCEHG-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000003561 anti-manic effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 238000009227 behaviour therapy Methods 0.000 description 2
- 208000028683 bipolar I disease Diseases 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XJEVHMGJSYVQBQ-SECBINFHSA-N (1r)-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2[C@H](N)CCC2=C1 XJEVHMGJSYVQBQ-SECBINFHSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- RFZXTZUXCINROI-UHFFFAOYSA-N 2-amino-1-(1-amino-2,3-dihydroinden-1-yl)ethanone Chemical compound C1=CC=C2C(C(=O)CN)(N)CCC2=C1 RFZXTZUXCINROI-UHFFFAOYSA-N 0.000 description 1
- LMHHFZAXSANGGM-UHFFFAOYSA-N 2-aminoindane Chemical compound C1=CC=C2CC(N)CC2=C1 LMHHFZAXSANGGM-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010004716 Binge eating Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010019079 Hallucinations, mixed Diseases 0.000 description 1
- 101100293260 Homo sapiens NAA15 gene Proteins 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021030 Hypomania Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 102100026781 N-alpha-acetyltransferase 15, NatA auxiliary subunit Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000000141 anti-hypoxic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000022257 bipolar II disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000009945 mood elevation Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 101150006061 neur gene Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16181799P | 1999-10-27 | 1999-10-27 | |
| US60/161,817 | 1999-10-27 | ||
| PCT/US2000/029618 WO2001030339A1 (en) | 1999-10-27 | 2000-10-27 | Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003512426A true JP2003512426A (ja) | 2003-04-02 |
| JP2003512426A5 JP2003512426A5 (enExample) | 2007-12-27 |
Family
ID=22582876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001532759A Pending JP2003512426A (ja) | 1999-10-27 | 2000-10-27 | 双極性気分障害における躁病の治療のための１−アミノインダンの使用。 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6492426B1 (enExample) |
| EP (1) | EP1242066B1 (enExample) |
| JP (1) | JP2003512426A (enExample) |
| AT (1) | ATE331508T1 (enExample) |
| AU (1) | AU775885B2 (enExample) |
| CA (1) | CA2387394C (enExample) |
| DE (1) | DE60029131T2 (enExample) |
| IL (2) | IL149308A0 (enExample) |
| WO (1) | WO2001030339A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014534196A (ja) * | 2011-10-10 | 2014-12-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9181026B2 (en) | 2013-10-03 | 2015-11-10 | Custom Chemical Solutions, LLC | Containment berm with internal “L” braces |
| WO2024196698A2 (en) * | 2023-03-17 | 2024-09-26 | Curadh Mtr | Compounds and constructs useful for targeting fibroblast activation protein |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3637740A (en) * | 1969-04-21 | 1972-01-25 | Pfizer | Aminobenzocycloalkane compounds |
| JPS53130644A (en) * | 1977-03-28 | 1978-11-14 | Lilly Co Eli | 11aminoindane compound |
| JPS5824433A (ja) * | 1981-08-06 | 1983-02-14 | Takehiro Mokuzai Kogyo Kk | 繊維材成型品の表面化粧方法 |
| JPH03294248A (ja) * | 1990-01-03 | 1991-12-25 | Teva Pharmaceut Ind Ltd | Ｎ−プロパルギル−１−アミノインダン化合物のｒ（＋）−鏡像体、それらの製造法およびそれらを含有する薬剤組成物 |
| JPH09510188A (ja) * | 1994-01-10 | 1997-10-14 | テバ・ファーマシューティカル・インダストリーズ・リミテッド | １−アミノインダン及びこれらの組成物 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB852735A (en) | 1956-04-13 | 1960-11-02 | Schering Ag | Manufacture of 1-aminoindanes |
| BE786748A (fr) * | 1971-07-26 | 1973-01-26 | Basf Ag | 1-aminomethyl-indanes-n-substitues |
| SE464194B (sv) | 1983-03-04 | 1991-03-18 | Otsuka Pharma Co Ltd | Indanderivat, foerfarande foer framstaellning daerav samt farmaceutiska kompositioner |
| EP0173331B1 (en) | 1984-08-31 | 1991-08-14 | Otsuka Pharmaceutical Co., Ltd. | 2,3-dihydro-1h-indene derivatives, a process for preparing them and pharmaceutical compositions containing same |
| US5242919A (en) | 1984-08-31 | 1993-09-07 | Otsuka Pharmaceutical Co., Ltd. | 2,3-dihydro-1H-indene derivatives |
| JPS6169747A (ja) | 1984-08-31 | 1986-04-10 | Otsuka Pharmaceut Co Ltd | ２，３―ジヒドロ―１ｈ―インデン誘導体及びその製造法 |
| US4882339A (en) | 1987-07-10 | 1989-11-21 | Ciba-Geigy Corporation | 4-Amino-substituted 1,2-dihydroxynaphthalene derivatives useful in inhibiting 5-lipoxygenase activity in mammals |
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| IL99759A (en) | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
| US5344836A (en) | 1991-11-11 | 1994-09-06 | Ono Pharmaceutical Co., Ltd. | Fused benzeneoxyacetic acid derivatives |
| CH683996A5 (fr) | 1992-03-05 | 1994-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et compositions pharmaceutiques les contenant. |
| KR100238346B1 (ko) | 1993-04-07 | 2000-03-02 | 오쓰까 아끼히꼬 | 피페리딘 유도체를 유효성분으로 하는 말초혈관확장제 |
| IL111240A (en) | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| CH690264A5 (fr) | 1995-06-30 | 2000-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques. |
| US5646188A (en) | 1995-07-05 | 1997-07-08 | Teva Pharmaceutical Industries, Ltd. | Polyamine derivatives of 1-aminoindan |
| IL115357A (en) | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| US5887218A (en) | 1996-06-10 | 1999-03-23 | Ricoh Co., Ltd. | Color image forming apparatus having toner and transfer sheet bearing members and image forming method thereof |
| DE69732984T2 (de) | 1996-12-18 | 2006-02-16 | Teva Pharmaceutical Industries Ltd. | Aminoindanderivate |
| US6251938B1 (en) | 1996-12-18 | 2001-06-26 | Teva Pharmaceutical Industries, Ltd., | Phenylethylamine derivatives |
| WO1998055447A1 (en) | 1997-06-05 | 1998-12-10 | Venantius Limited | 3-aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them |
| US5887221A (en) | 1997-10-20 | 1999-03-23 | Xerox Corporation | Signature sensing for optimum toner control with donor roll |
| US6227886B1 (en) | 1999-04-16 | 2001-05-08 | Avaya Technology Corp. | Snag-resistant patchcord plug latch and cover |
-
2000
- 2000-10-27 EP EP00976661A patent/EP1242066B1/en not_active Expired - Lifetime
- 2000-10-27 AT AT00976661T patent/ATE331508T1/de not_active IP Right Cessation
- 2000-10-27 CA CA002387394A patent/CA2387394C/en not_active Expired - Fee Related
- 2000-10-27 JP JP2001532759A patent/JP2003512426A/ja active Pending
- 2000-10-27 IL IL14930800A patent/IL149308A0/xx active IP Right Grant
- 2000-10-27 AU AU14402/01A patent/AU775885B2/en not_active Ceased
- 2000-10-27 DE DE60029131T patent/DE60029131T2/de not_active Expired - Lifetime
- 2000-10-27 US US09/699,127 patent/US6492426B1/en not_active Expired - Fee Related
- 2000-10-27 WO PCT/US2000/029618 patent/WO2001030339A1/en not_active Ceased
-
2002
- 2002-04-23 IL IL149308A patent/IL149308A/en not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3637740A (en) * | 1969-04-21 | 1972-01-25 | Pfizer | Aminobenzocycloalkane compounds |
| JPS53130644A (en) * | 1977-03-28 | 1978-11-14 | Lilly Co Eli | 11aminoindane compound |
| JPS5824433A (ja) * | 1981-08-06 | 1983-02-14 | Takehiro Mokuzai Kogyo Kk | 繊維材成型品の表面化粧方法 |
| JPH03294248A (ja) * | 1990-01-03 | 1991-12-25 | Teva Pharmaceut Ind Ltd | Ｎ−プロパルギル−１−アミノインダン化合物のｒ（＋）−鏡像体、それらの製造法およびそれらを含有する薬剤組成物 |
| JPH09510188A (ja) * | 1994-01-10 | 1997-10-14 | テバ・ファーマシューティカル・インダストリーズ・リミテッド | １−アミノインダン及びこれらの組成物 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014534196A (ja) * | 2011-10-10 | 2014-12-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1242066A4 (en) | 2004-09-01 |
| CA2387394A1 (en) | 2001-05-03 |
| AU1440201A (en) | 2001-05-08 |
| IL149308A0 (en) | 2002-11-10 |
| EP1242066B1 (en) | 2006-06-28 |
| WO2001030339A1 (en) | 2001-05-03 |
| CA2387394C (en) | 2009-08-18 |
| IL149308A (en) | 2007-07-24 |
| DE60029131D1 (de) | 2006-08-10 |
| US6492426B1 (en) | 2002-12-10 |
| ATE331508T1 (de) | 2006-07-15 |
| EP1242066A1 (en) | 2002-09-25 |
| AU775885B2 (en) | 2004-08-19 |
| DE60029131T2 (de) | 2007-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8883808B2 (en) | Combination of 5-HT7 receptor antagonist and serotonin reuptake inhibitor therapy | |
| US20100256145A1 (en) | Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted | |
| JP2002542287A (ja) | 医 薬 | |
| KR20030042037A (ko) | 하지불안증후군에 대한 신규 치료법 | |
| EP2468732B1 (en) | 1H-Quinazoline-2,4-diones | |
| JP2001516718A (ja) | ５−ＨＴ再取り込み阻害剤およびｈ５−ＨＴ１Ｂアンタゴニストまたは部分的アゴニストの組み合わせ | |
| US20140243350A1 (en) | Use of serotonin receptor agonists for treatment of movement disorders | |
| JP2002541105A (ja) | 神経学的障害または神経精神医学的障害を処置するための方法 | |
| JP2003012518A (ja) | 痙攣または発作を処置または予防するための組成物および方法 | |
| AU752192B2 (en) | The use of valproic acid analog for the treatment and prevention of migraine and affective illness | |
| US20140221385A1 (en) | Combinations of serotonin receptor agonists for treatment of movement disorders | |
| KR102301073B1 (ko) | 시노카브 또는 이의 약학적으로 허용가능한 염을 포함하는 약학적 조성물 및 이를 이용하여 운동이상증 및 관련 장애를 치료하는 방법 | |
| JP2003512426A (ja) | 双極性気分障害における躁病の治療のための１−アミノインダンの使用。 | |
| US20050119285A1 (en) | Treatment of neurological disorders related to rapid eye movement (REM) sleep disturbances with NPY Y5 receptor antagonists | |
| Tortella et al. | EEG seizure activity and behavioral neurotoxicity produced by (+)-MK801, but not the glycine site antagonist L-687,414, in the rat | |
| US20080242682A1 (en) | Preventive or Therapeutic Agent for Sleep Disorder | |
| CN114728961A (zh) | Kv7通道激活剂的使用方法 | |
| US20060189612A1 (en) | Pharmaceutically active morpholinol | |
| EP4052702A1 (en) | Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures | |
| JP2001516717A (ja) | 選択的５−ＨＴ１Ａアンタゴニストおよび選択的ｈ５−ＨＴ１Ｂアンタゴニストまたは部分的アゴニストの組み合わせ | |
| JP2014525474A (ja) | 光過敏性てんかんの予防または治療における使用のための１ｈ−キナゾリン−２，４−ジオンの使用 | |
| CN119451940A (zh) | 苯甲酰胺烯胺酮衍生物及其使用方法 | |
| JP2003532672A (ja) | フェルバマート誘導化合物 | |
| Dwivedi et al. | Overview Central & Peripheral Nervous Systems: Anti-epileptic agents: recent developments | |
| Abbasi et al. | Myoclonus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071026 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071026 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110118 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110628 |